Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.
about
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
P2860
Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Minimal residual disease detec ...... chronic lymphocytic leukemia.
@ast
Minimal residual disease detec ...... chronic lymphocytic leukemia.
@en
type
label
Minimal residual disease detec ...... chronic lymphocytic leukemia.
@ast
Minimal residual disease detec ...... chronic lymphocytic leukemia.
@en
prefLabel
Minimal residual disease detec ...... chronic lymphocytic leukemia.
@ast
Minimal residual disease detec ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P356
P1433
P1476
Minimal residual disease detec ...... n chronic lymphocytic leukemia
@en
P2093
A Nathwani
A Prentice
S G Agrawal
T W Farren
P2860
P2888
P356
10.1038/BCJ.2014.92
P577
2015-01-23T00:00:00Z